Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Files Patent Infringement Suit Against Several Firms

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic Technologies last week filed a patent infringement suit against several firms — including Beckman Coulter, Gen-Probe, and Orchid Cellmark — alleging infringement of a patent held by the Australian firm.

Genetic Technologies filed the suit in the US District Court for the Western District of Wisconsin on Friday. The company has alleged that several firms are infringing its US Patent No. 5,612,179, titled, "Intron Sequence Analysis Method for Detection of Adjacent Locus Alleles as Haplotypes."

In general, the patent relates to methods of analyzing non-coding DNA sequences.

Genetic Technologies has named several firms in the suit that are in the life sciences research, molecular diagnostics, and agricultural genomics market.

For example, it claims that Beckman Coulter's genomics services business utilizes a variety of commercially available instrument platforms that require Beckman to perform the step of amplification and enable analysis of non-coding segments of DNA. "Beckman's activities are an infringement of at least Claim 1 of the '179 Patent," Genetic Technologies asserted in the suit.

Meanwhile, agricultural giant Monsanto has been named in the suit for allegedly infringing the patent through its cattle genetics research programs.

In addition to these firms, the suit has named as defendants Interleukin Genetics, Molecular Pathology Laboratory Network, PIC USA, Pioneer Hi-Bred International, and Sunrise Medical Laboratories.

The patent at issue was previously asserted by Genetic Technologies in a suit brought against Applera, the former parent of Applied Biosystems, which is now part of Life Technologies. That suit ended with a settlement agreement in late 2005, under which Applera took a license to the '179 patent, among others.

Certain claims of the patent were recently subjected to a re-examination by the US Patent and Trademark Office, and according to Genetic Technologies, on Feb. 4, 2010, the USPTO confirmed the claims of the patent as valid without amendment.

The Australian firm has asked the court to find in its favor and declare that one or more claims of the '179 patent have been infringed by the defendants. It also has asked the court to award it damages and costs, including trebling the amount due to alleged willful infringement.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.